ReviewFrontiers in pharmacology2025
Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The anti-migratory effect of curcumin in colorectal cancer involves IKKβ/NF-κB/Snail-mediated EMT inhibition.Translational cancer research · 2026Article
- The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome.Chinese medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a prevalent malignant neoplasm of the digestive system, including 80% of primary liver malignancies. The Wnt/β-catenin signaling pathway plays a key role in immune response and tumer resistance. A growing number of studies have shown that the Wnt/β-catenin signaling pathway is involved in the pathogenesis of HCC. The Wnt/β-catenin pathway affects HCC in a variety of ways, including by influencing gene mutations, regulating dendritic cells, T-cells, and tumor cells, and influencing tumer resistance. Presently, conventional chemotherapy exhibits several drawbacks, including side effects, restrictions, and the emergence of tumer resistance. Traditional Chinese medicine (TCM) are characterized by multiple actions, multiple targets, few side effects, and improved immunity, and their combination with common clinical therapies can prolong patient survival and reduce postoperative recurrence rates, providing a new idea of combination therapy for the alleviation and improvement of HCC. This review focuses on TCM as an adjunct to surgery, targeted therapy, interventional therapy to improve the HCC microenvironment, reverse tumer resistance, and reduce treatment side effects by modulating the Wnt signaling pathway. It should be clear that TCM should not replace the first-line treatment plan of modern medicine, and its core value is to improve the comprehensive efficacy and quality of life of patients. This research examines the role of the Wnt/β-catenin signalling system in developing HCC and describes how TCM and plant active metabolites, crude extracts of single botanical drugs and Chinese herbal formulations affect the progression of HCC by modulating different targets of the Wnt/β-catenin signalling pathway or by modulating other pathways related to the Wnt/β-catenin signalling pathway. This review is intended to provide new ideas and options for the prevention and treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.